From Johnson & JohnsonSep 24 2024 Johnson & Johnson today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking the first approval of nipocalimab globally for the treatment of people living with generalized myasthenia gravis (gMG). The application included data from the Phase 3 Vivacity-MG3 study...
Tag: <span>Myasthenia gravis</span>
Post
Benefits of thymectomy in treating myasthenia gravis
JULY 2, 2024 by Ellen Goldbaum, University at Buffalo T cell development in the thymus. Credit: Neurology (2024). DOI: 10.1212/WNL.0000000000209482The first-ever randomized study of the removal of the thymus gland in treating myasthenia gravis was conducted in 2016. Led by Gil I. Wolfe, MD, SUNY Distinguished Professor and the Irvin and Rosemary Smith Professor of...
Post
FDA approves Zilbrysq for generalized myasthenia gravis
by Lori Solomon The U.S. Food and Drug Administration has approved UCB’ Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis. Zilbrysq is a targeted peptide inhibitor of complement component 5 (C5) and is approved as a once-daily, self-administered, targeted therapy in patients with anti-acetylcholine receptor (AChR)-antibody-positive generalized myasthenia gravis. The approval of...
Post
Leading the way in Myasthenia Gravis (MG) detection
Reviewed by Olivia Frost MG, an autoimmune disease, occurs when the body’s immune system produces antibodies that attack vital proteins at the neuromuscular junctions, impacting the skeletal muscles responsible for breathing and various movements. It is estimated that this chronic neuromuscular disorder impacts over 700,000 individuals worldwide. Image Credit: ShutterStock/Kateryna Kon Early and accurate diagnosis...
Post
Researchers report on rozanolixizumab, zilucoplan phase 3 myasthenia gravis study
by Mark Derewicz, University of North Carolina at Chapel Hill School of Medicine Patient with Myasthenia Gravis. Credit: Cumulus at Dutch Wikipedia, CC BY-SA 3.0 , via Wikimedia Commons The Lancet Neurology has published data from the phase 3 MycarinG study evaluating the efficacy and safety of rozanolixizumab in adult patients with acetylcholine receptor autoantibody-positive (AChR-Ab+) or muscle-specific...
Post
Researchers identify specific cells that contribute to the pathology of myasthenia gravis combined with thymus tumor
by Osaka University Proposed MG pathology in thymoma. Credit: Nature Communications (2022). DOI: 10.1038/s41467-022-31951-8 Autoimmune diseases occur when a person’s antibodies mistakenly recognize their body’s own cells as foreign invaders and attack them. One such disease is myasthenia gravis (MG), where the antibodies target neuromuscular-associated proteins. MG is common in patients with thymoma, a type of tumor...
Post
Understanding infection risks in patients with myasthenia gravis
by Jennifer Stranges, St. Michael’s Hospital Myasthenia gravis (MG) is a serious autoimmune neuromuscular disease. Immunosuppression or immunomodulating therapies are used to treat patients with MG but have the potential to suppress or alter the immune system, with infections being one major risk. Dr. Charles Kassardjian, a neurologist and researcher at St. Michael’s Hospital, recently...
Post
FDA approves eculizumab for generalized myasthenia gravis
Yesterday the U.S. Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. James F. Howard Jr., MD, Distinguished Professor of Neuromuscular Disease, professor of neurology, medicine and allied health, and chief of the Neuromuscular Disorders Section in the UNC School...